Proxima
Senior Research Associate
Boston · Senior
Sponsorship not specifiedDetected 92 days ago
Machine LearningData AnalysisResearchMass SpectrometryProtein AnalysisAnimal StudiesOrganizational Skills
About the role
- This role will focus on running XLMS sample preparation and LC-MS workflows end-to-end, learning routine maintenance of our next-generation mass spectrometry instrumentation, and contributing to the scale-up of proteome-wide interaction mapping.
- You will work closely with proteomics scientists, computational biologists, and chemists to generate the proprietary XLMS data that trains Neo-1 and powers our drug discovery pipeline.
Responsibilities
- Operate and maintain HPLC and LC-MS systems
- Perform protein expression and purification (bacterial and mammalian systems) to support XLMS substrate preparation
- Maintain accurate experimental records in the electronic lab notebook and adhere to strong documentation standards
- Support platform scale-up by writing and refining SOPs, training teammates, and identifying automation opportunities
- Collaborate closely with computational biologists, chemists, and other scientists to integrate XLMS data into structural biology and drug discovery workflows
Requirements
- Bachelor's/Masters degree in Biochemistry, Chemistry, Biology, or a related scientific discipline
- Demonstrated proficiency in mass spectrometry workflows, with hands-on LC-MS experience required
- Prior experience with cross-linking mass spectrometry (XLMS) workflows
- Experience with click chemistry enrichment and affinity-tag-based peptide capture
- Experience with automated sample preparation platforms (e.g., Hamilton, Opentrons)
Company info
- About Proxima
- Proxima (formerly VantAI) is advancing an AI-native approach to drug discovery by making protein interactions programmable.
- Our platform brings together foundation-model machine learning, a scalable data generation engine, and a partnership track record exceeding $5B in collaborations across the world's leading biopharma and tech organizations.
- We've recently closed an oversubscribed seed round partnering us with an elite group of sophisticated and dedicated VCs including DCVC, Nvidia's Nventures, AIX, Yosemite among others.
- Neo-1 is our all-atom foundation model that combines state-of-the-art structure prediction and molecular generation in a single system.
- Neo-1 enables rapid exploration of chemical and structural space for high value, previously intractable targets, and in particular unlocks small molecule proximity therapeutics like molecular glues with AI for the first time.
- In parallel, Proxima is developing an advanced structural interactomics platform built on proprietary cross-linking mass spectrometry (XLMS) technology and a lab equipped with next-generation mass spectrometry instrumentation.
- This platform produces proteome-scale interactome maps and helps identify small molecules that modulate protein interactions.
- Together with Neo-1, it creates an integrated system capable of co-folding protein complexes while also generating candidate small molecules to influence those interactions.
- Based on these proprietary capabilities, Proxima is developing a robust pipeline of first-in-class medicines across several therapeutic areas including immunology and inflammation, cardiometabolic and aggregate-driven diseases.
- The company is currently advancing multiple assets through preclinical development that address both novel and well validated targets.
Apply directly at Proxima →Create a free account for alerts like thisView Proxima immigration profile
This listing is sourced directly from Proxima's careers page and normalized into a canonical job model.